Valeant Pharmaceuticals (VRX) is one of the pharmaceutical companies that’s focused on developing and commercializing prescription pharmaceuticals, generic pharmaceuticals, over-the-counter products, and eye care products.
The above chart shows analysts’ recommendations for Valeant in the past 12 months.
Valeant reported revenues of ~$2.0 billion during the first quarter—a 5.4% decline compared to $2.1 billion during the first quarter of 2017. Wall Street analysts expect revenues of ~$2.1 billion during the second quarter. Later in this series, we’ll provide a detailed analysis of the company’s revenues and EPS.
Valeant’s stock price has doubled in the past 12 months. The stock increased more than 105.0% in the last 12 months, while the stock price has increased ~20.1% in 2018 year-to-date. However, analysts expect the stock price to decrease ~14.1% in the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $21.43 per share—compared to the last price of $24.95 per share as of June 7.
As of June 8, there are 17 analysts tracking Valeant stock. Two analysts recommend a “strong buy,” five analysts recommend a “buy,” six analysts recommend a “hold,” three analysts recommend a “sell,” and one analyst recommends a “strong sell.” The consensus rating for Valeant stands at 2.76, which represents a moderate “buy” for value investors.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!